tiprankstipranks
Kezar Life Sciences reports Q4 EPS (25c), consensus (28c)
The Fly

Kezar Life Sciences reports Q4 EPS (25c), consensus (28c)

Cash, cash equivalents and marketable securities totaled $276.6 million as of December 31, 2022, compared to $208.4 million as of December 31, 2021. The increase was primarily attributable to net proceeds from the issuance of common stock, net of cash used in operations to advance clinical-stage programs and preclinical research and development. "We made tremendous progress in both of our first-in-class programs during 2022," said John Fowler, Kezar’s CEO. "These successes include reporting positive Phase 2 MISSION data with zetomipzomib in lupus nephritis, selecting autoimmune hepatitis as the next indication in that program, making continued progress in our Phase 1 study with KZR-261, and presenting exciting preclinical findings from our Protein Secretion Inhibition Platform. We plan to build on this momentum in 2023, with the initiation of the PALIZADE trial in lupus nephritis patients, launching our PORTOLA trial in autoimmune hepatitis, as well as sharing topline results on the dose escalation portion of our Phase 1 study with KZR-261 in solid tumors. With our strong team and solid balance sheet, we are well positioned to deliver meaningful results across both programs in 2023 and beyond."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles